DUP 105
| 中文名称 | DUP 105 |
|---|---|
| 中文同义词 | 化合物 T11123;化合物DUP 105 |
| 英文名称 | 4-methylsulfinylphenyloxooxazolidinylmethylacetamide |
| 英文同义词 | 4-methylsulfinylphenyloxooxazolidinylmethylacetamide;(5S)-5-Acetylaminomethyl-3-(4-methylsulfinylphenyl)oxazolidin-2-one;DuP-105;N-[[(5S)-3-[4-(Methylsulfinyl)phenyl]-2-oxooxazolidin-5-yl]methyl]acetamide;Acetamide, N-[[(5S)-3-[4-(methylsulfinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-;(S)-N-<<3-<4(S)-(methylsulfinyl)phenyl>-2-oxo-5-oxazolidinyl>methyl>acetamide |
| CAS号 | 96800-41-8 |
| 分子式 | C13H16N2O4S |
| 分子量 | 296.34 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 96800-41-8.mol |
| 结构式 |  |
DUP 105 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
DuP 105 是一种可口服的恶唑烷酮类化合物，能够抗葛兰素阳性菌。
DuP 105 shows inhibitory activities against staphylococcal isolates and B. fragilis isolates with MIC 90 s of 4 to 16 μg/mL and 16 μg/mL. DuP 105 MICs for 50% of the 216 gram-positive isolates tested (MIC 50 s) range from 4.0 to 16 μg/mL.
DuP 105 administered by either the oral or the parenteral route is protective against staphylococcal and streptococcal infections in mice with the 50% effective doses of 9 to 23 mg/kg.